Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma

Abstract

BACKGROUND. Anemia is a well-recognized complication of concurrent chemora-

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

“…In previous studies, prechemotherapy Hgb level was the most commonly reported risk factor for anemia on treatment or requirement for transfusion [1, 6,9,18]. Other reported risk factors include age older than 65 [11], hemoglobin decrease during the first month of chemotherapy [6], duration of chemotherapy [6], tumor type [1, 6], previous transfusions [6,7], platinum-based chemotherapy [1] and platinum pharmacokinetics [23], multiple concurrent chemotherapeutic agents [25], female sex [1], performance status (PS)>1 [24], pretreatment absolute lymphocyte count (ALC) lower than 700/μl [24]. Our data set did not permit us to test all these reported risk factors, but our results are consistent.…”

Serum hypoxia‐inducible factor‐2: A candidate prognostic biomarker for laryngeal cancer

“…28 Of note, approximately 80% of patients with HNC may develop mild-to-severe anaemia that has a negative impact on treatment tolerance and causes treatment failure. 29 Moreover, smoking may aggravate anaemia in patients with lung and HNCs. Therefore, WHO recommends evaluating 'smoking-adjusted anaemia'.…”

Anaemia in elderly patients with cancer: Focus on chemotherapy-induced anaemia

“…8,31 The immediacy of the effect of RBC transfusions makes them particularly useful when treating patients with life-threatening anaemia. 32 It is also the treatment recommended in the current ASCO and the ASH guidelines for severe anaemia (defined as a Hb level of <8 g/dL).…”